Fusion Biopsy Market Route (Transrectal, Transperineal), End-use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), Key Players (MedCom, ESAOTE SPA, KOELIS, Focal Healthcare, GeoScan Medical, UC-Care Medical Systems Ltd) and Region (North America, Europe, Asia Pacific, Middle East and Africa, and South America) Global Forecast 2018 to 2028

Two major revolutions have changed cancer treatment paradigms in the past few years: targeting actionable alterations in oncogene-driven cancers and immuno-oncology. Important challenges are still ongoing in both fields of cancer therapy. On the one hand, druggable genomic alterations are diverse and represent only small subsets of patients in certain tumor types, which limits testing their clinical impact in biomarker-driven clinical trials. Next-generation sequencing technologies are increasingly being implemented for molecular prescreening in clinical research, but issues regarding clinical interpretation of large genomic data make their wide clinical use difficult.

Prostate cancer is the most common non-skin cancer in America; 1 in 6 men will be diagnosed with prostate cancer. And the older you are, the more likely you are to be diagnosed with prostate cancer. Although only 1 in 10,000 under age 40 will be diagnosed, the rate shoots up to 1 in 39 for ages 40 to 59, and 1 in 14 for ages 60 to 69. In fact, about 65% of all prostate cancers are diagnosed in men over the age of 65. But the roles of race and family history are important as well. Although genetics might play a role in deciding why one man might be at higher risk than another, social and environmental factors, particularly diet and lifestyle, likely have an effect as well. The exact relationship between obesity and prostate cancer remains unclear, but there is no doubt that obesity can have a negative effect on outcomes.

On the basis of biopsy route, the transrectal segment accounted for the largest revenue share, while transperineal fusion biopsy is set to grow at the fastest CAGR.

As the second most diagnosed cancer worldwide, prostate cancer is confirmed via tissue biopsy. Given the large number of prostate biopsies performed each year, the technique should be as accurate and safe as possible for the patient’s well-being. Tissue biopsy can be obtained using either transrectal ultrasound guided biopsy (TRUS-biopsy) or transperineal prostate biopsy (TPP-biopsy). TRUS-biopsy is the most commonly offered worldwide as it can be performed in a clinic setting with local anaesthesia. TPP-biopsy is typically a day procedure often requiring general anaesthesia. TPP biopsy was first described in the 1970s but has recently become more widely adopted as it has shown to be superior in sensitivity especially in detecting anterior cancers, as well as having a lower rate of sepsis compared to TRUS-biopsies. Due to the indolent nature of insignificant (low risk) forms of prostate cancer and morbidity associated with treatment, avoiding the diagnosis of clinically insignificant disease is of increasing importance. The optimal prostate biopsy technique should aim to have a high detection rate of clinically significant PCa whilst also having a low detection rate of insignificant PCa. Given the high number of prostate biopsies performed each year, biopsy must be accessible, time-efficient and cost-effective to ensure feasibility for patients and health care systems.

North America dominated the market for fusion biopsy in 2020, which is closely followed by Europe. However, Asia Pacific is anticipated to witness a highest CAGR.

Prostate cancer is the fourth most common cancer overall and the second most common cancer in men. Worldwide, there are estimated to have been 1.1 million men diagnosed with prostate cancer (accounting for 15% of all incident cancer cases in men), with almost 70% of the cases occurring in more developed regions. Prostate cancer incidence varies by a factor of more than 25 worldwide; the rates are highest in Australia/New Zealand and North America and in western and northern Europe, because the practice of prostate specific antigen (PSA) testing and subsequent biopsy has become widespread in those regions. Incidence rates are also relatively high in certain less developed regions, such as the Caribbean, southern Africa and South America but remain low in Asian populations. Its incidence shows arise in India. It is the second leading site of cancer in Indian cities like Delhi, Kolkata and Pune. It is the 3 leading site in cities like Mumbai and Bangalore. In India, it has an incidence rate of 3.9 per 1,00,000 men and is responsible for 9% of cancer related mortality.